SCHEMBL6578141

SCHEMBL6578141

Cc1ccc2c(c1)C(O)(C(=O)O)CCO2

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1B1 P15121 2/20 0.44
RARA P10276 3/20 0.40
RARB P10826 3/20 0.40
RARG P13631 3/20 0.40
NPC1 O15118 6/20 0.40
RAB9A P51151 6/20 0.40
RXRA P19793 1/20 0.39
CTNNB1 P35222 1/20 0.38
WNT3A P56704 1/20 0.38
APP P05067 2/20 0.38
BACE1 P56817 2/20 0.38
MAP3K14 Q99558 1/20 0.37
ALDH1A1 P00352 3/20 0.37
GAA P10253 1/20 0.37
MAPT P10636 1/20 0.37
HSD17B10 Q99714 1/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
HPGD P15428 1/20 0.37
KDM4E B2RXH2 1/20 0.36
LMNA P02545 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6578015 0.82 AKR1B1 (0.64) AKR1B1CTNNB1MAPT
SCHEMBL6605552 0.82 MAP3K14 (0.49) AKR1B1RARARARBRARGNPC1
SCHEMBL6605548 0.82 MAP3K14 (0.49) AKR1B1RARARARBRARGNPC1
SCHEMBL5399703 0.82 MAP3K14 (0.49) AKR1B1RARARARBRARGNPC1
SCHEMBL6580916 0.81 RAB9A (0.43) AKR1B1RARARARBRARGNPC1
SCHEMBL27999909 0.78 AKR1B1 (0.41) AKR1B1MAP3K14ALDH1A1GAAMAPT
SCHEMBL8795191 0.77 AKR1B1 (0.49) AKR1B1RARARARBRARGNPC1
SCHEMBL20480667 0.77 MAP3K14 (0.42) AKR1B1RARARARBRARGNPC1
SCHEMBL20997335 0.74 AKR1B1 (0.44) AKR1B1RARARARBRARGCTNNB1
SCHEMBL15233631 0.74 BACE1 (0.40) AKR1B1RARARARBRARGNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1012140-B1 NEW AMIDINO DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS ASTRAZENECA AB (SE) 2004-09-29 EP disclosed
US-6576657-B2 Nitrogen containing heterocyclic compounds useful as anticoagulants ASTRAZENECA AB (SE) 2003-06-10 US disclosed
US-20020022612-A1 New amidino derivatives and their use as thrombin inhibitors ASTRAZENECA AB 2002-02-21 US disclosed
US-6265397-B1 Amidino derivatives and their use as thrombin inhibitors ASTRAZENECA AB (SE) 2001-07-24 US disclosed
EP-1012140-A1 NEW AMIDINO DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS AstraZeneca AB (SE) 2000-06-28 EP disclosed
WO-1998057932-A1 NEW AMIDINO DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS ASTRA AKTIEBOLAG (SE) 1998-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020022612-A1 New amidino derivatives and their use as thrombin inhibitors SERPINC1, SERPINE1, SERPINB1 AKR1B1 1664/4885RARA 4036/4885RARB 3222/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.